WuXi AppTec (HKG:2359) expects an attributable profit of around 8.56 billion yuan in the first half of 2025, up 102% from 4.24 billion yuan a year prior, a Thursday Hong Kong bourse filing said.
The drug research and development company attributed the anticipated rise in profit mainly to the enhancement of its capacity, optimization of production processes, and improved operating efficiency, as well as investment income from sale of part of WuXi XDC Cayman.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.